Description: Zelda Therapeutics Limited, formerly Gleneagle Gold Limited, is engaged in mineral exploration of gold and base metals, and the assessment of investment opportunities. Its projects include Milly Well, Berring Pool, Chester North and Chester South. It operates over four leases on its projects, which are located in the Cue Mineral Field. Three of the leases are contiguous being E20/742 and P20/2095 and P20/2096. The fourth lease, EL20/833, is situated to the north west of Milly Bore. The Milly Bore project is situated within the Archaean Meekatharra-Wydgee Greenstone Belt. The principal deposits in Milly Bore are Black Swan, Black Swan South, Golden Gate, Chieftain and Rheingold. The Berring Pool project covers an area of approximately 16 square Kms and is also situated within the Archaean Meekatharra-Wydgee Greenstone Belt. The Chester North project covers an area of over 154 hectares and Chester South covers an area of over 131 hectares.
Home Page: www.zeliratx.com
ZLD Technical Analysis
101 St George's Terrace
Perth,
WA
6000
Australia
Phone:
61 8 6558 0886
Officers
| Name | Title |
|---|---|
| Mr. Osagie O. Imasogie Esq. | Founder & Chairman |
| Dr. Oludare Odumosu | MD, Global CEO & Director |
| Mr. Timothy Ryan Slate | Non-Exec. Director & Company Sec. |
| Mr. Rahul Ganesan | VP of Fin. & Accounting |
| Mr. Greg Blake | VP of Global and Head of Commercial & Partnering |
| Dr. Patty Washer | Clinical Trial Consultant |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2721 |
| Price-to-Sales TTM: | 6.6515 |
| IPO Date: | 2003-07-28 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |